New nasal spray aims to sneeze away dust mite allergies

NCT ID NCT04088721

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a nasal spray called AD17002 in 48 adults with house dust mite allergic rhinitis. The goal was to see if it is safe and can reduce symptoms like sneezing, runny nose, and congestion. Participants received either the spray or a placebo, and researchers monitored side effects and symptom scores.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
AD17002 (a nasal spray immunomodulator)
What this could lead to
If it works, this could lead to a new nasal spray treatment that eases allergy symptoms from dust mites.
What could go wrong
This was a small, early-phase trial with only 48 people, so results may not apply widely. The treatment may not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLERGIC RHINITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Taipei Medical University

    Taipei, Taiwan, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.